Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1041-1060 of 2,251 trials

Severe Diffuse Cutaneous Systemic Sclerosis: Rapcabtagene Autoleucel vs. Rituximab

We are studying a new treatment to see if it works better than rituximab for people with severe diffuse cutaneous systemic sclerosis. The trial will also evaluate the safety of this new therapy.

Systemic Scleroderma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Tranexamic Acid for Postoperative Complications in Plastic Surgery

We are studying whether applying tranexamic acid to surgical wounds can reduce re-bleeding and other complications after plastic surgery. This trial includes both men and women over 18 years old.

Healthy Participants Undergoing SurgeryMonitoring phase (IV)No PlaceboStandard MedicinesHematologyOrthopedics and Traumatology

Multiple Myeloma: Teclistamab with Lenalidomide

We are studying a new treatment combining teclistamab and lenalidomide for patients with newly diagnosed multiple myeloma after stem cell transplant. The aim is to see if this combination works better than lenalidomide alone in maintaining remission.

Newly Diagnosed Multiple MyelomaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Postoperative Sleep Quality: DEXSLEEP Study

We are testing whether dexmedetomidine can improve sleep and reduce fatigue in elderly patients after major surgery. This may help enhance recovery and overall well-being following surgery.

Healthy Participants Aged 60 and Older1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPsychiatry

Benzodiazepine Dependence: Stabilizing Treatment Study

We are examining how a stable dose of benzodiazepines affects people with benzodiazepine dependence who are also receiving opioid therapy. The study looks at impacts on drug use, mental and physical health, and overall quality of life.

Benzodiazepine Dependence1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicinePsychiatry

Crigler-Najjar Syndrome: GNT0003 Treatment Study

We are evaluating a new treatment called GNT0003 for adults with severe Crigler-Najjar syndrome who need daily phototherapy. The study aims to see if this treatment is safe and effective for those with pre-existing antibodies.

Crigler-Najjar Syndrome>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHepatologyInternal Medicine

Advanced Solid Tumors and Blood Cancer: Durvalumab and Tremelimumab Study

We are testing the safety and early effectiveness of Durvalumab alone and with Tremelimumab in children with advanced solid tumors and blood cancers. This study aims to find the best dosage and understand how these treatments work.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

HER2-Altered Cancers: Zongertinib Study

We are testing whether zongertinib can help people with advanced solid tumors that have HER2 mutations or overexpression. The study will evaluate its effectiveness, safety, and how patients respond to the treatment.

HER2-mutated or overexpressed/amplified solid tumorsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Acute Myeloid Leukemia: Gemtuzumab Ozogamicin with Chemotherapy

We are studying whether adding gemtuzumab ozogamicin to standard chemotherapy helps reduce minimal residual disease in adults with newly diagnosed acute myeloid leukemia. This research aims to improve treatment outcomes and overall survival.

Favorable-Intermediate-Risk Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Meningococcal Disease: New Pentavalent Vaccine for Children

We are studying a new vaccine to see if it is safe and effective for healthy children, toddlers, and infants against meningococcal disease. The trial compares this vaccine with currently licensed options to evaluate immune responses.

Meningococcal Immunization1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesPediatrics

Pancreatic Cancer: SGM-101 Imaging Study

We are testing a new imaging agent to help surgeons better see pancreatic tumors during surgery. This study aims to improve the accuracy of tumor detection and assess the extent of cancer in patients who have received prior treatment.

Pancreatic Tumor3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal MedicineOncology

Psilocybin Therapy for Depression in Serious Illnesses

We are studying whether medium/high doses of psilocybin can help reduce depression and anxiety in patients with COPD, ALS, MS, or APD. This research aims to improve their quality of life and support their caregivers.

Chronic Respiratory and Neurological Disorders≤3 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatryPulmonology

Pancreatic Cancer: Organoid-Based Treatment Selection

We are studying whether lab-grown mini-tumors can help choose better post-surgery treatments for patients with resectable pancreatic cancer. This may improve recovery and outcomes after surgery.

Pancreatic Ductal Adenocarcinoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Heart Transplant in Children: Comparing Custodiol and Custodiol-N

We are studying the safety of two organ preservation solutions during heart transplants in children. This research aims to see which solution better supports recovery and overall health after surgery.

Heart Transplantation in Children>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyPediatrics

Locally Advanced NSCLC: New Chemoradiotherapy Approach

We are studying a new FDG-PET-based treatment for patients with locally advanced non-small cell lung cancer. The goal is to see if this method is safer and more effective than the standard treatment.

Stage III Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Tau Imaging in Alzheimer's: Comparing PET Tracers

We are comparing three different PET tau tracers in volunteers to see which one best measures tau levels in the brain. This research may help improve diagnosis and treatment monitoring for Alzheimer's disease.

Cognitive Impairment>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOtolaryngology

Acute Myeloid Leukemia: KO-539 Treatment Study

We are testing a new drug called KO-539 in patients with relapsed or refractory acute myeloid leukemia. The goal is to see if it is safe and effective for those with specific genetic mutations.

Relapsed Acute Myeloid Leukemia≤3 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Advanced Solid Tumors: DF6002 Treatment Study

We are investigating the safety and effectiveness of DF6002, alone and with Nivolumab, for patients with advanced solid tumors. This study aims to find the best dose and understand how well the treatment works.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesOncology

High-Risk Myelodysplastic Syndromes: Stem Cell Transplantation Study

We are evaluating a new treatment approach that combines hypomethylating therapy with stem cell transplantation for patients with high-risk myelodysplastic syndromes. The study aims to assess the feasibility and safety of this combined treatment.

Myelodysplastic SyndromeConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematology

B-Cell Acute Lymphoblastic Leukemia: Inotuzumab Ozogamicin Study

We are examining whether Inotuzumab can help adults with B-Cell Acute Lymphoblastic Leukemia achieve MRD negativity before stem cell transplantation. The study will also look at treatment safety and survival rates.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology